Article
Vasoactive Intestinal Peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.
2025-05-16
Abstract excerpt
<title>Abstract</title> <p> Current therapies for osteoarthritis (OA) focus on symptom management, rather than halting disease progression. Vasoactive intestinal peptide (VIP) has shown promising effects in musculoskeletal diseases, preserving joint integrity and modulating inflammation. This study investigates the potential of VIP to promote chondrogenic differentiation of human bone marrow mesenchymal stem cel...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ceab36a8-c95e-5c76-b485-69c0679eab46
- DOI
- 10.21203/rs.3.rs-6529495/v1
